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Abstract
Background: Hepatitis C is an infectious disease affecting the liver, caused by the hepatitis C virus (HCV). The
hepatitis C virus is a small, enveloped, single-stranded, positive sense RNA virus with a large genetic heterogeneity.
Isolates have been classified into at least eleven major genotypes, based on a nucleotide sequence divergence of
30-35%. Genotypes 1, 2 and 3 circulate around the world, while other genotypes are mainly restricted to
determined geographical areas. Genotype determination of HCV is clinically valuable as it provides important
information which can be used to determine the type and duration of therapy and to predict the outcome of the
disease.
Results: Plasma samples were collected from ninety seven HCV RNA positive patients admitted to two large
medical laboratory centers in Isfahan province (Iran) from the years 2007 to 2009. Samples from patients were
subjected to HCV genotype determination using a PCR based genotyping kit. The frequency of HCV genotypes
was determined as follows: genotype 3a (61.2%), genotype 1a (29.5%), genotype 1b (5.1%), genotype 2 (2%) and
mixed genotypes of 1a+3a (2%).
Conclusion: Genotype 3a is the most frequent followed by the genotype 1a, genotype 1b and genotype 2 in
Isfahan province, Iran.
Background
Hepatitis C virus (HCV) is a small enveloped virus first
isolated in 1989 and belongs to the family of flaviviridae
[1]. Its genome is composed of a positive-sense, single-
stranded RNA encoding a polyprotein comprising struc-
tural (core and envelope glycoproteins E1 and E2) and
non-structural (NS2, NS3a/b, NS4a/b and NS5a/b) pro-
teins. Acute HCV infection is often asymptomatic and
approximately 70% of all cases progress to chronic hepa-
titis. This may lead to progressive liver disease, cirrhosis,
liver failure and hepatocellular carcinoma within 20 to
30 years. Factors associated with disease progression fol-
lowing infection include the viral genotype, the patient’s
alcohol consumption and viral load [2]. Determination
of the HCV genotype provides clinically important
information that can be used to direct the type and
duration of anti-viral therapy and to predict the
likelihood of sustained HCV clearance after therapy
[3,4]. Patients with HCV genotype 1 may benefit from a
longer course of therapy and genotypes 2 and 3 are
more likely to respond to a combination of interferon
and Ribavirin therapy [5]. Most genotyping methods
include a first step of reverse transcription (RT) of viral
RNA and polymerase chain reaction (PCR) amplifica-
tion. The conserved 5’ non-coding region of the HCV
genome has been used as a target for a number of diag-
nostic assays. This region can be characterized by probe
hybridization or by variation in restriction patterns [6,7].
Global patterns for the distribution of different HCV
genotypes are as follows:
1a is mostly found in North and South America, also
common in Australia.
1b is mostly found in Europe and Asia.
2a is the most common genotype 2 in Japan and
China.
2b is the most common genotype 2 in the US and
north Europe.
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2c is the most common genotype 2 in western and
southern Europe.
3a is highly prevalent in Australia (40% of cases) and
south Asia.
4a is highly prevalent in Egypt.
4c is highly prevalent in central Africa.
5a is highly prevalent only in south Africa.
6a is restricted to Hong Kong, Macau and Vietnam.
7a and 7b are common in Thailand.
8a, 8b and 9a are prevalent in Vietnam.
10a and 11a are found in Indonesia [8].
The aim of the present study is to determine the fre-
quency of HCV genotypes in Isfahan province, Iran.
Results
Patients were referred to two medical centers in Isfahan
by specialists and were suspected of hepatitis. They were
screened primarily for anti HCV antibodies. Samples
from one hundred and forty-six patients who were posi-
tive for anti HCV antibodies were subjected to conven-
tional RT-PCR for detection of HCV RNA (Figure 1).
Ninety seven patients were identified positive for HCV
nucleic acid. The mean age of the HCV nucleic acid
positive patients was 35 years (16-78 years). Ninety-five
subjects (97.9%) were male and two (2.1%) were female.
Samples from these HCV RNA positive patients were
used in a genotype determining method based on PCR
technique. In this method different genotypes generate
PCR products which are different in sizes (Figure 2).
Genotypes of HCV were determined in all ninety seven
patients. Genotypes 1a, 1b, 2 and 3a were detected and
in some cases mixed infections with more than one gen-
otype (1a+3a) were revealed. Predominant genotypes
were genotype 3a (61.2%), 1a (29.5%) and 1b (5.1%). A
less frequent genotype was genotype 2 (2%). There were
also two cases with mixed genotype infection of 1a and
3a (2%) (Figure 3).
Discussion
Hepatitis C infection may lead to a substantial health
and economic burden over the next 10 to 20 years.
From a public health perspective, the implementation of
molecular tests as an integral part of the diagnostic and
therapeutic management of infections with HCV should
be imperative. Due to different treatment schedules
between genotype 1 (48 weeks) and genotypes 2 and 3
(24 weeks), genotype distribution has a significant influ-
ence on the total costs and morbidity of HCV treat-
ment. Nucleotide sequence analysis may be regarded as
the gold standard for the identification of different HCV
genotypes and subtypes, but it is generally believed to
be impractical for routine clinical laboratory settings.
Several alternative HCV genotyping procedures have
therefore been suggested which are usually based on the
Figure 1 A representative agarose gel electrophoresis of PCR products for the detection of HCV nucleic acid in plasma of patients
positive for anti HCV antibodies. Plasma samples from anti-HCV antibody positive patients were subjected to RT-PCR using general primers
which are able to detect HCV nucleic acid by generating a 227 bp product. Lanes 1 and 8: 100 bp DNA size marker, lane 2: positive control,
lanes 3 and 6: patients positive for HCV nucleic acid, lane 4: negative control, lanes 5 and 7: patients negative for HCV nucleic acid.
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Figure 2 Two representative agarose gels of PCR products demonstrating different HCV genotypes. Plasma samples from patients
positive for HCV nucleic acid were subjected to genotype determination using a specific RT-PCR kit which produces different size PCR products
related to different genotypes. A) Lanes 1, 6 and 11: 100 bp DNA size marker, lane 2: positive control for genotype 1a (338 bp), lane 3: positive
control for genotype 1b (395 bp), lane 4: positive control for genotype 2 (286 bp), lane 5: positive control for genotype 3a (227 bp), lanes 7 and
8: two sets of PCR amplifications for one patient resulting in genotype 3a, lanes 9 and 10: two sets of PCR amplifications for another patient
resulting in genotype 1a. B) Lanes 1, 6 and 12: 100 bp DNA size marker, lane 2: positive control for genotype 1a (338 bp), lane 3: positive control
for genotype 1b (395 bp), lane 4: positive control for genotype 2 (286 bp), lane 5: positive control for genotype 3a (227 bp), lanes 7 and 8: two
sets of PCR amplifications for one patient resulting in genotype 1a, lane 9: empty well, lane 10: patient positive for genotype 2, lane 11: patients
positive for genotype 1b.
Figure 3 Frequency of different HCV genotypes in Isfahan province of Iran. HCV genotypes were determined in ninety-seven HCV RNA
positive patients admitted to two large medical centers between 2007 and 2009 in Isfahan province, Iran. Predominant genotypes were: 3a (61.2%),
1a (29.5%) and 1b (5.1%). Less frequent was genotype 2 (2%). Mixed genotype infection of 1a and 3a was also observed in two cases (2%).
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analysis of PCR products by hybridization with geno-
type-specific probes or restriction length polymorphism
analysis. In a routine diagnostic virology laboratory, sim-
pler, faster and less expensive methods are required. In
this study, we used a commercial RT-PCR genotyping
kit which is able to determine common HCV genotypes
in less than a few hours. This investigation was per-
formed in Isfahan province, one of the most populated
provinces, of Iran. HCV genotype 3a was found to be
the most prevalent (61.2%), followed by genotype 1a
(29.5%), 1b (5.1%), genotype 2 (2%) and mixed geno-
types of 1a plus 3a (2%). The genotypes of all ninety-
seven HCV nucleic acid positive patients were revealed
by this kit. Although the kit used in this study was able
to detect only genotypes 1a, 1b, 2 and 3a, all the sam-
ples were identified suggesting that the common geno-
types are those reported here. We cannot rule out the
possibility of mix infection with genotypes which the kit
is not designed to detect, though according to the litera-
ture, other genotypes in that area are very rare.
There are several reports regarding the distribution of
different HCV genotypes in different parts of Iran. In a
population-based study 116 samples from HCV RNA
positive patients from different parts of Iran were ana-
lyzed using PCR-RFLP. The authors reported that 1a,
3a, and 1b were the predominant genotypes with an
overall prevalence rate of 61.2%, 25% and 13.8% respec-
tively [9]. In a study in Fars province (Iran), during
2004-2005, among 188 subjects with HCV infection,
44.1% were genotype la, 42.0% genotype 3a and 13.8%
genotype 1b [10]. They used Nested-PCR and PCR-
RFLP for genotyping and stated that genotypes other
than those reported could not be found in that area. In
comparison with studies made in Iran’s neighbor coun-
tries, it can be understood that the most common geno-
type in Kuwait, Iraq, and Saudi Arabia is type 4 [11].
However, genotype 1b in Turkey in the western border
of Iran and genotype 3a in Pakistan in the eastern bor-
der of Iran are more prevalent [12,13]. Although geno-
type 4 is found almost exclusively in Middle East and
western countries [14], this genotype is very uncommon
in Iran. From different studies conducted in different
parts of Iran, it generally could be concluded that geno-
types 1a and 3a are the most prevalent in Iran while 1b
and 2 are less frequent and other genotypes are rare
[9,15]. A similarity has been reported between Iran and
both Pakistan and India, in which genotype 3 is very
prevalent and genotype 2 is rare [16,17]. It could be due
to the high rate of immigration from these countries to
Iran, especially when considering the fact that the preva-
lence of HCV infection in these countries is higher than
in Iran. Genotypes 3a and 1a are more prevalent in
intra-venous drug abusers (IVDU) in Europe and USA
[18-20]. In the present study, 85 patients (86.5%) were
IV drug abusers among whom HCV genotype 3a and 1a
were more prevalent. It seems that there is a high simi-
larity between the pattern of genotype in IVDU in Eur-
ope, the United States and Iran.
Conclusion
In conclusion, our results are in accordance with other
reports demonstrating the predominance of genotypes
3a and 1a and a very low frequency of genotype 2 in
Iran which is different from Europe, USA and even
some parts of Asia [11,21-24].
Methods
Patients and study design
This is a descriptive cross-sectional study. Patients who
were suspected of hepatitis were referred to two large
medical centers by specialists in Isfahan province (Iran)
between March 2007 and April 2009. They were
screened primarily for anti-HCV antibodies using a
commercial ELISA kit. Those who were positive for
anti-HCV antibodies were selected for HCV RNA detec-
tion using the RT-PCR technique. Out of 146 anti-HCV
antibody positive patients, 97 were positive for HCV
RNA. Patients who were positive for anti-HCV antibo-
dies but were negative for HCV RNA were under treat-
ment and were excluded. All samples from HCV RNA
positive patients were selected for the study and were
subjected to HCV genotype determination using com-
mercial RT-PCR based kit. A waiver of consent was pro-
vided by the executive ethics committee of the medical
center, as the samples used in this study were surplus to
requirements following diagnostic investigations.
Plasma samples
Ten ml venous blood samples were collected from each
patient referred to the laboratory. Blood samples were
collected in tubes containing EDTA. Centrifuged and
separated plasmas were immediately stored at -80°C. To
avoid RNA degradation, aliquots were not thawed more
than once prior to analysis.
HCV RNA detection
Plasma samples were tested for the presence of HCV
nucleic acid using, with general primers, the conven-
tional RT-PCR commercial kit (Qiagen, Germany)
which is able to detect all different HCV genotypes.
Tests were conducted according to manufacturer’s
recommendations. Briefly they were as follows: 50 μl
plasma was added to 5.6 μl RNA carrier and 560 μl of
lysis buffer, incubated at room temperature for 10 min
before having 560 μl of ethanol (96-100%) added. 630 μl
of the solution was transferred to the Minispin column,
centrifuged at 6000 g for 1 min and then the spin col-
umn was placed into a clean 2 ml collection tube, the
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tube containing the filtrate being discarded. Subse-
quently 500 μl of washing buffer was added and centri-
fuged at 6000 g for 1 min, again the tube containing the
filtrate was discarded. 500 μl of elution buffer was added
and centrifuged at full speed for 3 min. Finally, 60 μl of
dissolving buffer was added to the last spin column to
collect the RNA. Small aliquots of isolated RNA were
tested to assess the quality and quantity of RNA using a
spectrophotometer (Eppendorf, Germany). Two μg of
RNA was reverse-transcribed into cDNA using a master
mix of 5XRT mix, M-MLV reverse-transcribe enzyme,
RNAse inhibitor, dNTPs and ddH2O and then placed
on a thermal cycler (Eppendorf, Germany) at 37°C for
30 min. Five μl of cDNA was subjected to PCR amplifi-
cations using general primers included in the kit, which
is able to amplify all different genotypes of HCV. The
PCR program was as follows: initial denaturation at 95°
C for 5 min, and then 45 cycles at 95°C for 30 sec, 57°C
for 15 sec, 72°C for 30 sec and a final extension at 72°C
for 5 min. PCR products were subjected to electrophor-
eses and separation on 2% agarose gel, being visualized
under UV light after ethidium bromide staining.
HCV genotyping
Samples positive for HCV RNA were subjected to HCV
genotyping using a commercial kit (Sacace, Italy)
according to manufacturer’s recommendations. This kit
is designed for the detection of genotypes 1a, 1b, 2, 3a
(most common HCV genotypes in Iran) by generating
different size PCR products. The specificity and sensitiv-
ity of the kit are 100% and 1000 viral particles per ml
respectively according to the manufacturer. For each
patient two sets of PCR amplifications were carried out
in two separate tubes containing primers for either gen-
otypes 1a+1b or genotypes 2+3a. Five μl of cDNA was
subjected to PCR amplifications using two sets of mixed
primers included in the kit. The PCR program was as
follows: initial denaturation at 95°C for 5 min, and then
42 cycles of 95°C for 1 min, 68°C for 1 min, 72°C for 1
min and a final extension at 72°C for 10 min. Genotype
1a generates a 338 bp PCR product, 1b 395 bp, 2 286
bp and 3a 227 bp. PCR products were electrophoresed,
separated by 2% agarose gel and visualized under UV
light after ethidium bromide staining.
Acknowledgements
This study was supported in part by Mahdieh Diagnostic Centre Charity,
Isfahan, Iran. Authors are grateful of University of Isfahan for its support.
Authors would like to thank Mr. MG Copeland for revision of the manuscript.
Author details
1Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan,
81746-73695, IR, IRAN. 2Department of Immunology, Medical School, Isfahan
University of Medical Sciences, Hezar Jerib Street, Isfahan, 81746-73695, IR,
IRAN. 3Department of Biology, Faculty of Sciences, University of Isfahan,
Hezar Jerib Street, Isfahan, 81746-73695, IR, IRAN. 4Department of Pathology,
Medical School, Isfahan University of Medical Sciences, Hezar Jerib Street,
Isfahan, 81746-73695, IR, IRAN.
Authors’ contributions
SHZ supervised the experiments and contributed to data analysis and the
preparation of the manuscript. MTK performed all the experiments and
contributed to data analysis. MA contributed to data analysis and the
preparation of the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 24 November 2009 Accepted: 24 March 2010
Published: 24 March 2010
References
1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation
of a cDNA clone derived from a blood-borne non-A, non-B viral
hepatitis genome. Science 1989, 244:359-362.
2. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR,
Marinos G, Kaldor JM: Estimating progression to cirrhosis in chronic
hepatitis C virus infection. Hepatology 2001, 34:809-816.
3. EASL International Consensus Conference on Hepatitis C. Paris, 26-28,
February 1999, Consensus Statement. European Association for the
Study of the Liver. J Hepatol 1999, 30:956-961.
4. National Institutes of Health Consensus Development Conference
Panel statement: management of hepatitis C. Hepatology 1997,
26:2S-10S.
5. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK,
Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in
combination with ribavirin as initial treatment for chronic hepatitis C.
Hepatitis Interventional Therapy Group. N Engl J Med 1998,
339:1485-1492.
6. Krekulova L, Rehak V, Wakil AE, Harris E, Riley LW: Nested restriction site-
specific PCR to detect and type hepatitis C virus (HCV): a rapid method
to distinguish HCV subtype 1b from other genotypes. J Clin Microbiol
2001, 39:1774-1780.
7. Ross RS, Viazov S, Wolters B, Roggendorf M: Towards a better resolution of
hepatitis C virus variants: CLIP sequencing of an HCV core fragment and
automated assignment of genotypes and subtypes. J Virol Methods 2008,
148:25-33.
8. Ramia S, Eid-Fares J: Distribution of hepatitis C virus genotypes in the
Middle East. Int J Infect Dis 2006, 10:272-277.
9. Amini S MFMAM, Alavian SM, Joulaie M, Ahmadipour MH: Distribution of
hepatitis C Virus Genotypes in Iran: a Population-Based Study. Hepatitis
Monthly 2009, 9:95-102.
10. Davarpanah MA SM, Bagheri Lankarani K, Mehrabani D, Behzad-
Behbahani A, Serati A, Ardebili M, Yousef M, Khademolhosseini F, Keyvani-
Amineh H: Hepatitis C Virus Genotype distribution is Shiraz, Southern
Iran. Hepatitis Monthly 2009, 9:122-127.
11. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E,
Yap PL, Kolberg J, Urdea MS: Classification of hepatitis C virus into six
major genotypes and a series of subtypes by phylogenetic analysis of
the NS-5 region. J Gen Virol 1993, 74(Pt 11):2391-2399.
12. Abacioglu YH, Davidson F, Tuncer S, Yap PL, Ustacelebi S, Yulug N,
Simmonds P: The distribution of hepatitis C virus genotypes in Turkish
patients. J Viral Hepat 1995, 2:297-301.
13. Shah HA, Jafri W, Malik I, Prescott L, Simmonds P: Hepatitis C virus (HCV)
genotypes and chronic liver disease in Pakistan. J Gastroenterol Hepatol
1997, 12:758-761.
14. Mellor J, Holmes EC, Jarvis LM, Yap PL, Simmonds P: Investigation of the
pattern of hepatitis C virus sequence diversity in different geographical
regions: implications for virus classification. The International HCV
Collaborative Study Group. J Gen Virol 1995, 76(Pt 10):2493-2507.
15. Zali MR, Mayumi M, Raoufi M, Nowroozi A: Hepatitis C virus genotypes in
the Islamic Republic of Iran: a preliminary study. East Mediterr Health J
2000, 6:372-377.
16. Khokhar N, Asif N, Khokhar OS: Serotype 3 is most common hepatitis C
serotype in Pakistan: however, significant numbers are untypeable.
Hepatology 2003, 38:270-271.
Zarkesh-Esfahani et al. Virology Journal 2010, 7:69
http://www.virologyj.com/content/7/1/69
Page 5 of 6
17. Chowdhury A, Santra A, Chaudhuri S, Dhali GK, Maity SG, Naik TN,
Bhattacharya SK, Mazumder DN: Hepatitis C virus infection in the general
population: a community-based study in West Bengal, India. Hepatology
2003, 37:802-809.
18. McOmish F, Chan SW, Dow BC, Gillon J, Frame WD, Crawford RJ, Yap PL,
Follett EA, Simmonds P: Detection of three types of hepatitis C virus in
blood donors: investigation of type-specific differences in serologic
reactivity and rate of alanine aminotransferase abnormalities. Transfusion
1993, 33:7-13.
19. Pistello M, Maggi F, Vatteroni L, Cecconi N, Panicucci F, Bresci GP,
Gambardella L, Taddei M, Bionda A, Tuoni M, et al: Prevalence of hepatitis
C virus genotypes in Italy. J Clin Microbiol 1994, 32:232-234.
20. Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J,
Dhumeaux D: Relationship between hepatitis C virus genotypes and
sources of infection in patients with chronic hepatitis C. J Infect Dis 1995,
171:1607-1610.
21. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, Cobain TJ,
Krusius T, Kolho E, Naukkarinen R, et al: Geographical distribution of
hepatitis C virus genotypes in blood donors: an international
collaborative survey. J Clin Microbiol 1994, 32:884-892.
22. Bukh J, Purcell RH, Miller RH: At least 12 genotypes of hepatitis C virus
predicted by sequence analysis of the putative E1 gene of isolates
collected worldwide. Proc Natl Acad Sci USA 1993, 90:8234-8238.
23. Simmonds P: Variability of hepatitis C virus. Hepatology 1995, 21:570-583.
24. Viazov S, Zibert A, Ramakrishnan K, Widell A, Cavicchini A, Schreier E,
Roggendorf M: Typing of hepatitis C virus isolates by DNA enzyme
immunoassay. J Virol Methods 1994, 48:81-91.
doi:10.1186/1743-422X-7-69
Cite this article as: Zarkesh-Esfahani et al.: Hepatitis C virus genotype
frequency in Isfahan province of Iran: a descriptive cross-sectional
study. Virology Journal 2010 7:69.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zarkesh-Esfahani et al. Virology Journal 2010, 7:69
http://www.virologyj.com/content/7/1/69
Page 6 of 6
